Entities / Infrastructure
Sarepta.
Infrastructure
- Reports this week
- 0
- Active events
- 0
- Connections
- 24
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
The EMA issued a negative opinion on July 25, 2025, recommending the rejection of Sarepta's Elevidys application for European clearance.Some support2 reports
-
Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.Speculative1 report
-
Market volatility was observed in the health sector, driven by Sarepta's gene therapy trials being halted by the FDA due to patient liver failure, alongside broader market concerns affecting the S&P index.Some support1 report
-
Arrowhead Pharmaceuticals and Sarepta entered into a collaboration regarding siRNA programs, including licensing agreement payments starting on August 19, 2025.Well supported4 reports1 development inside
-
Diane Berry was appointed as the executive vice president of Sarepta in September 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Sarepta this week
News at the entities that move Sarepta most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Sarepta
Connections
The 4 strongest of 24, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Doug Ingram Structural
Doug Ingram serves as the chief executive officer of Sarepta, leading its financial strategy.
-
FDA Structural
The FDA exercises formal regulatory authority over Sarepta's drug development, shipment, and clinical practices.
-
Arrowhead Pharmaceuticals Operational
Arrowhead and Sarepta maintain an ongoing operational collaboration through licensing agreements and milestone payments.
-
Arrowhead Structural
Sarepta structurally depends on Arrowhead's drug platform, following an initial stock sale transaction.
History
Events by the month they beganJune 2026
7 events- Roche commercialized a treatment after partnering with Sarepta, while Sarepta simultaneously faced a regulatory pause in the U.S.
- Doug Ingram was appointed Chief Executive Officer of Sarepta on August 21, 2025.
- The EMA issued a negative opinion on July 25, 2025, recommending the rejection of Sarepta's Elevidys application for European clearance.
- Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
- Market volatility was observed in the health sector, driven by Sarepta's gene therapy trials being halted by the FDA due to patient liver failure, alongside broader market concerns affecting the S&P index.
- Arrowhead Pharmaceuticals and Sarepta entered into a collaboration regarding siRNA programs, including licensing agreement payments starting on August 19, 2025.
- Diane Berry was appointed as the executive vice president of Sarepta in September 2025.